Search

Your search keyword '"Lavine CL"' showing total 40 results

Search Constraints

Start Over You searched for: Author "Lavine CL" Remove constraint Author: "Lavine CL" Language english Remove constraint Language: english
40 results on '"Lavine CL"'

Search Results

1. Antibody-mediated SARS-CoV-2 entry in cultured cells.

2. Structural and functional characteristics of the SARS-CoV-2 Omicron subvariant BA.2 spike protein.

3. Autologous neutralizing antibodies increase with early antiretroviral therapy and shape HIV rebound after treatment interruption.

4. Subtle Longitudinal Alterations in Env Sequence Potentiate Differences in Sensitivity to Broadly Neutralizing Antibodies following Acute HIV-1 Subtype C Infection.

5. Vaccine breakthrough infection leads to distinct profiles of neutralizing antibody responses by SARS-CoV-2 variant.

6. Structural and functional characteristics of SARS-CoV-2 Omicron subvariant BA.2 spike.

7. Structural and functional impact by SARS-CoV-2 Omicron spike mutations.

8. Vaccine Breakthrough Infection with the SARS-CoV-2 Delta or Omicron (BA.1) Variant Leads to Distinct Profiles of Neutralizing Antibody Responses.

9. Membrane fusion and immune evasion by the spike protein of SARS-CoV-2 Delta variant.

10. Memory B cell repertoire for recognition of evolving SARS-CoV-2 spike.

11. Membrane fusion and immune evasion by the spike protein of SARS-CoV-2 Delta variant.

12. Structural basis for enhanced infectivity and immune evasion of SARS-CoV-2 variants.

13. Structural basis for enhanced infectivity and immune evasion of SARS-CoV-2 variants.

14. Memory B cell repertoire for recognition of evolving SARS-CoV-2 spike.

15. A trimeric human angiotensin-converting enzyme 2 as an anti-SARS-CoV-2 agent.

16. Quick COVID-19 Healers Sustain Anti-SARS-CoV-2 Antibody Production.

17. A trimeric human angiotensin-converting enzyme 2 as an anti-SARS-CoV-2 agent in vitro.

18. A minor population of macrophage-tropic HIV-1 variants is identified in recrudescing viremia following analytic treatment interruption.

19. Differential Outcomes following Optimization of Simian-Human Immunodeficiency Viruses from Clades AE, B, and C.

20. HIV-1 fusion inhibitors targeting the membrane-proximal external region of Env spikes.

21. HIV-1 Neutralizing Antibody Signatures and Application to Epitope-Targeted Vaccine Design.

22. HIV-1 Neutralizing Antibody Signatures and Application to Epitope-Targeted Vaccine Design.

23. Paired quantitative and qualitative assessment of the replication-competent HIV-1 reservoir and comparison with integrated proviral DNA.

24. Production of Mucosally Transmissible SHIV Challenge Stocks from HIV-1 Circulating Recombinant Form 01_AE env Sequences.

25. Glycan-Dependent Neutralizing Antibodies Are Frequently Elicited in Individuals Chronically Infected with HIV-1 Clade B or C.

26. Protective efficacy of adenovirus/protein vaccines against SIV challenges in rhesus monkeys.

27. A multivalent clade C HIV-1 Env trimer cocktail elicits a higher magnitude of neutralizing antibodies than any individual component.

28. Generation and evaluation of clade C simian-human immunodeficiency virus challenge stocks.

29. Infection of monkeys by simian-human immunodeficiency viruses with transmitted/founder clade C HIV-1 envelopes.

30. Common features of mucosal and peripheral antibody responses elicited by candidate HIV-1 vaccines in rhesus monkeys.

31. Vaccine delivery with microneedle skin patches in nonhuman primates.

32. High-mannose glycan-dependent epitopes are frequently targeted in broad neutralizing antibody responses during human immunodeficiency virus type 1 infection.

33. Epitopes for broad and potent neutralizing antibody responses during chronic infection with human immunodeficiency virus type 1.

34. Identification of Francisella tularensis lipoproteins that stimulate the toll-like receptor (TLR) 2/TLR1 heterodimer.

35. The AcrAB RND efflux system from the live vaccine strain of Francisella tularensis is a multiple drug efflux system that is required for virulence in mice.

36. Immunization with heat-killed Francisella tularensis LVS elicits protective antibody-mediated immunity.

37. IL-12-assisted immunization against Listeria monocytogenes using replication-restricted VSV-based vectors.

38. Recombinant replication-restricted VSV as an expression vector for murine cytokines.

39. IL-12-assisted immunization generates CD4+ T cell-mediated immunity to Listeria monocytogenes.

40. Differential indicators of diabetes-induced oxidative stress in New Zealand White rabbits: role of dietary vitamin E supplementation.

Catalog

Books, media, physical & digital resources